Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

De-TIL-0255

Cell therapy (Tumor-infiltrating lymphocytes) · Kills target cells · developed by Nurix Therapeutics

Phase 1 Most advanced trial (none active)
NRIX Developer
1 Registered trials

What is De-TIL-0255?

De-TIL-0255 is an autologous tumor-infiltrating lymphocyte cell therapy, made from a patient's own lymphocytes taken from tumor tissue. It is studied in platinum-resistant ovarian cancer, endometrial cancer and cervical cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (Tumor-infiltrating lymphocytes)
Mechanism
Kills target cells
Therapy area
Oncology
Developer
Nurix Therapeutics, Inc. (NRIX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05107739 Phase 1 Platinum-resistant Ovarian Cancer Terminated NRIX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cervical CancerEndometrial CancerPlatinum-resistant Ovarian Cancer

More from Nurix Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NRIX page.

Follow NRIX, the company behind De-TIL-0255

See NRIX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NRIX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.